{
    "nct_id": "NCT04634409",
    "official_title": "A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)",
    "inclusion_criteria": "* For low-risk participant arms 9-11 only: Are greater than or equal to (≥)18 and less than (<)65 years of age at the time of randomization and do not have the risk factors defined in the bullet point directly below\n* For high-risk participant arms 12 and 13 only:\n\n  -- Are ≥18 years of age and satisfy at least one of the following risk factors at the time of screening\n  * Are ≥65 years of age\n  * Have a body mass index (BMI) ≥ 35\n  * Have chronic kidney disease\n  * Have type 1 or type 2 diabetes\n  * Have immunosuppressive disease\n  * Are currently receiving immunosuppressive treatment, or\n  * Are ≥55 years of age AND have\n\n    * cardiovascular disease, OR\n    * hypertension, OR\n    * chronic obstructive pulmonary disease or other chronic respiratory disease\n* For high-risk participant arms 12 and 13 only:\n\n  * Are 12-17 years of age (inclusive) AND satisfy at least one of the following risk factors at the time of screening\n\n    * Have a BMI ≥85th percentile for their age and gender based on CDC growth charts, https://www.cdc.gov/growthcharts/clinical_charts.htm\n    * Have sickle cell disease\n    * Have congenital or acquired heart disease\n    * Have neurodevelopmental disorders, for example, cerebral palsy\n    * Have a medical-related technological dependence, for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19)\n    * Have asthma or reactive airway or other chronic respiratory disease that requires daily medication for control\n    * Have type 1 or type 2 diabetes\n    * Have chronic kidney disease\n    * Have immunosuppressive disease, or\n    * Are currently receiving immunosuppressive treatment.\n\nFor high-risk participants arm 14 only:\n\n* Are ≥12 years of age and satisfy at least one of the following risk factors at the time of screening Are ≥65 years of age\n* Are adults (≥18 years of age) with BMI >25 kg/m2 , or if age 12-17, have BMI ≥85th percentile for their age and gender based on CDC growth charts\n* Have chronic kidney disease\n* Have type 1 or type 2 diabetes\n* Have immunosuppressive disease\n* Are currently receiving immunosuppressive treatment\n* Have cardiovascular disease (including congenital heart disease) or hypertension\n* Have chronic lung diseases (for example, chronic obstructive pulmonary disease, asthma [moderate-to-severe], interstitial lung disease, cystic fibrosis and pulmonary hypertension)\n* Have sickle cell disease\n* Have neurodevelopmental disorder (for example, cerebral palsy) or other conditions that confer medical complexity (for example, genetic or metabolic syndromes and severe congenital anomalies)\n* Have a medical-related technological dependence (for example, tracheostomy, gastrostomy, or positive pressure ventilation [not related to COVID-19]\n* Are currently not hospitalized\n* Have one or more mild or moderate COVID-19 symptoms: Fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, or shortness of breath with exertion, nasal congestion or runny nose, new loss of smell, chills\n* Must have sample taken for test confirming viral infection no more than 3 days prior to starting the drug infusion\n* Are men or non-pregnant women who agree to contraceptive requirements\n* Understand and agree to comply with planned study procedures\n* Agree to the collection of nasopharyngeal swabs and venous blood\n* The participant or legally authorized representative give signed informed consent and/or assent\nHealthy volunteers allowed\nMust have minimum age of 12 Years",
    "exclusion_criteria": "* For low-risk participants only: BMI ≥35\n* Have oxygen saturation (SpO2) less than or equal to (≤)93 percent (%) on room air at sea level or ratio of arterial oxygen partial pressure (PaO2 in millimeters of mercury) to fractional inspired oxygen (FiO2) <300, respiratory rate ≥30 per minute, heart rate ≥125 per minute\n* Require mechanical ventilation or anticipated impending need for mechanical ventilation\n* Have known allergies to any of the components used in the formulation of the interventions\n* Have hemodynamic instability requiring use of pressors within 24 hours of randomization\n* Suspected or proven serious, active bacterial, fungal, viral, or other infection (besides COVID-19) that in the opinion of the investigator could constitute a risk when taking intervention\n* Have any co-morbidity requiring surgery within <7 days, or that is considered life-threatening within 29 days\n* Have any serious concomitant systemic disease, condition or disorder that, in the opinion of the investigator, should preclude participation in this study\n* Have a history of a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test prior to the one serving as eligibility for this study\n* Have received an investigational intervention for SARS-CoV-2 prophylaxis within 30 days before dosing\n* Have received treatment with a SARS-CoV-2 specific monoclonal antibody\n* Have a history of convalescent COVID-19 plasma treatment\n* For low-risk arms only: have received a SARS-CoV-2 vaccine or have participated in a previous SARS-CoV-2 vaccine study and are currently blinded to treatment allotment\n* Have participated, within the last 30 days, in a clinical study involving an investigational intervention. If the previous investigational intervention has a long half-life, 5 half-lives or 30 days, whichever is longer, should have passed\n* Are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study\n* Are pregnant or breast feeding\n* Are investigator site personnel directly affiliated with this study\n* Have body weight <40 kilograms",
    "miscellaneous_criteria": ""
}